Department of Neurosurgery, Klinikum rechts der Isar, Technical University of Munich (TUM), Ismaninger Str. 22, 81675, Munich, Germany.
Center for Personalized Medicine (ZPM), Klinikum rechts der Isar, Technical Universitiy of Munich (TUM), Munich, Germany.
BMC Cancer. 2024 Jan 19;24(1):108. doi: 10.1186/s12885-024-11858-x.
In neuro-oncology, the inclusion of tumor patients in the molecular tumor board has only become increasingly widespread in recent years, but so far there are no standards for indication, procedure, evaluation, therapy recommendations and therapy implementation of neuro-oncological patients. The present work examines the current handling of neuro-oncological patients included in molecular tumor boards in Germany.
We created an online based survey with questions covering the handling of neuro-oncologic patient inclusion, annotation of genetic analyses, management of target therapies and the general role of molecular tumor boards in neuro-oncology in Germany. We contacted all members of the Neuro-Oncology working group (NOA) of the German Cancer Society (DKG) by e-mail.
38 responses were collected. The majority of those who responded were specialists in neurosurgery or neurology with more than 10 years of professional experience working at a university hospital. Molecular tumor boards (MTB) regularly take place once a week and all treatment disciplines of neuro-oncology patients take part. The inclusions to the MTB are according to distinct tumors and predominantly in case of tumor recurrence. An independently MTB member mostly create the recommendations, which are regularly implemented in the tumor treatment. Recommendations are given for alteration classes 4 and 5. Problems exist mostly within the cost takeover of experimental therapies. The experimental therapies are mostly given in the department of medical oncology.
Molecular tumor boards for neuro-oncological patients, by now, are not standardized in Germany. Similarities exists for patient inclusion and interpretation of molecular alterations; the time point of inclusion and implementation during the patient treatment differ between the various hospitals. Further studies for standardization and harmonisation are needed. In summary, most of the interviewees envision great opportunities and possibilities for molecular-based neuro-oncological therapy in the future.
在神经肿瘤学中，近年来肿瘤患者纳入分子肿瘤委员会的情况越来越普遍，但目前仍缺乏神经肿瘤患者纳入的指征、程序、评估、治疗建议和治疗实施的标准。本研究调查了德国纳入分子肿瘤委员会的神经肿瘤患者的当前处理情况。
我们创建了一个基于在线的调查，其中包含了有关神经肿瘤患者纳入、遗传分析注释、靶向治疗管理以及分子肿瘤委员会在神经肿瘤学中的一般作用的问题。我们通过电子邮件联系了德国癌症协会（DKG）神经肿瘤学工作组（NOA）的所有成员。
共收集到 38 份回复。回复者大多是神经外科或神经内科的专家，具有 10 年以上在大学医院工作的专业经验。分子肿瘤委员会（MTB）定期每周举行一次会议，所有神经肿瘤患者的治疗学科都参加。MTB 的纳入是根据不同的肿瘤进行的，主要是在肿瘤复发的情况下。独立的 MTB 成员主要制定建议，这些建议通常在肿瘤治疗中实施。建议适用于改变类别 4 和 5。主要存在实验性治疗费用接管方面的问题。实验性治疗大多在肿瘤内科进行。
目前，德国的神经肿瘤学患者的分子肿瘤委员会尚未标准化。患者纳入和分子改变的解释存在相似之处；在患者治疗过程中，纳入和实施的时间点在不同的医院有所不同。需要进一步的标准化和协调研究。总的来说，大多数受访者对未来基于分子的神经肿瘤治疗的机会和可能性持乐观态度。
